“Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s129. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1991.